Global Longlife Hospital And Research Ltd vs Jupiter Life Line Hospitals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Global Longlife Hospital and Research Ltd is ₹ 12.57 as of 23 Oct 15:30 . The P/E Ratio of Global Longlife Hospital and Research Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Jupiter Life Line Hospitals Ltd changed from 44.5 on March 2024 to 43 on March 2026 . This represents a CAGR of -1.14% over 3 years The Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Jupiter Life Line Hospitals Ltd changed from ₹ 7853 crore on March 2024 to ₹ 8344 crore on March 2026 . This represents a CAGR of 2.04% over 3 years The revenue of Global Longlife Hospital and Research Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Jupiter Life Line Hospitals Ltd for the Sep '26 is ₹ 467.04 crore as compare to the Jun '26 revenue of ₹ 421.57 crore. This represent the growth of 10.79% The ebitda of Global Longlife Hospital and Research Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Jupiter Life Line Hospitals Ltd for the Sep '26 is ₹ 117.39 crore as compare to the Jun '26 ebitda of ₹ 89.86 crore. This represent the growth of 30.64% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of 0.0% The net profit of Jupiter Life Line Hospitals Ltd changed from ₹ 44.61 crore to ₹ 56.36 crore over 10 quarters. This represents a CAGR of 9.80% The Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Jupiter Life Line Hospitals Ltd changed from 4.32 % on March 2024 to 3.43 % on March 2026 . This represents a CAGR of -7.40% over 3 years .

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution that offer to every human being, high quality healthcare at affordable prices in Ahmedabad. Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

About Jupiter Life Line Hospitals Ltd

Jupiter Life Line Hospitals Limited was incorporated in Mumbai, Maharashtra through a Certificate of Incorporation dated November 18, 2002, issued by the RoC, which subsequently, commenced its business operations in December, 2002.
Led by founding Promoter, Dr. Ajay Thakker, the Company is a prominent multi-speciality tertiary and quaternary healthcare service provider in the Mumbai metropolitan area and Western India with total operational bed capacity of 1,194 across three hospitals located in Thane, Pune and Indore under the 'Jupiter' brand.
The Company is constructing a new multi-speciality hospital in Dombivali, Maharashtra with potential capacity of 500 beds.
The Company is also running Fortune Park Lake City Hotel in Thane for promoting medical tourism. The Company follow a patient first' ideology by creating the best infrastructure, technology and support to put the patient first and foremost and be futuristic and innovative in delivery of healthcare.

FAQs for the comparison of Global Longlife Hospital and Research Ltd and Jupiter Life Line Hospitals Ltd

Which company has a larger market capitalization, Global Longlife Hospital and Research Ltd or Jupiter Life Line Hospitals Ltd?

Market cap of Global Longlife Hospital and Research Ltd is 13 Cr while Market cap of Jupiter Life Line Hospitals Ltd is 8,007 Cr

What are the key factors driving the stock performance of Global Longlife Hospital and Research Ltd and Jupiter Life Line Hospitals Ltd?

The stock performance of Global Longlife Hospital and Research Ltd and Jupiter Life Line Hospitals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Global Longlife Hospital and Research Ltd and Jupiter Life Line Hospitals Ltd?

As of October 25, 2026, the Global Longlife Hospital and Research Ltd stock price is INR ₹12.57. On the other hand, Jupiter Life Line Hospitals Ltd stock price is INR ₹244.25.

How do dividend payouts of Global Longlife Hospital and Research Ltd and Jupiter Life Line Hospitals Ltd compare?

To compare the dividend payouts of Global Longlife Hospital and Research Ltd and Jupiter Life Line Hospitals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.